

ON THE STATE OF FUNCTIONAL ACTIVITY OF THE SYMPATHETIC-ADRENAL SYSTEM AND FREE RADICAL PROCESSES IN WOMEN OF FERTILE AGE WITH METABOLIC SYNDROME

Tashtemirova I. M.

Andijan State Medical Institute

Abstract: The aim of the given work was study interactions of impairments sympathetic – adrenal systems functional condition and processes of peroxidal oxidation of lipids in woman of fertile age with metabolic syndrome. 91 women at the age of 25-49 were observation. They were randomized into 3 groups: I (control) – 15 healthy persons, II – 39 patients with arterial hypertension, III – 37 women with arterial hypertension in combination with metabolic syndrome. The results of carried investigations showed that activation of sympathetic adrenal system and processes of peroxidal oxidation of lipids took place in metabolic syndrome. Marked lowering of sympathetic – adrenal system key ferment catecholamins (MAO monoaminooxidaze) desamidization activity and considerable activation of peroxidal oxidation of lipid products which have great significance in revealing the mechanism of metabolic syndrome development were observed in metabolic syndrome. This results in the prolonged toxic influence of catecholamins on myocardium.

Key words: metabolic syndrome, sympathetic–adrenal system, catecholamins, arterial hypertension, insulinresistens.

Introduction. Clustering of risk factors for cardiovascular diseases (CVD) in recent decades has shown that the mortality rate is largely influenced by the following factors: obesity, type 2 diabetes mellitus (DM), arterial hypertension (AH), insulin resistance (IR), hyperinsulinemia (GI), and hyperlipidemia. It is known that each of these factors included in the definition of "metabolic syndrome" increases the risk of heart disease. An increase in blood pressure (BP) on the background of obesity is often accompanied by an increase in the activity of the sympathetic nervous system [1,2,3,4,5]. Hypertension is often one of the first clinical manifestations of MS. Recent data indicate a widespread prevalence of obesity in women. Being a continuously progressive somatic disease, obesity contributes to the formation of a wide range of cardiovascular disorders. The high incidence of abdominal obesity is noteworthy [6,7,8,9]. The processes of lipid peroxidation (LPO) lead to the accumulation of oxidized low-density lipoproteins (LDL), which leads to a violation of microcirculation. From this point of view, the study of LPO processes in MS has become particularly interesting, since one of the main biochemical parameters of blood in this case is an increase in the level of biogenic amines in the blood. Recent studies suggest that biogenic amines (epinephrine, norepinephrine, serotonin, etc.) should be studied to understand atherosclerosis, hypertension, CHD, and diabetes mellitus (DM.) and their precursors, metabolic products and enzymes involved in their metabolism [2, 9, 10, 11,12]. Often, the state of the sympathetic-adrenal system (SAS) was not studied in a complex: either only individual fractions of catecholamines (CA) were studied, or the content of CA and its degradation products in MS patients was studied. The study of the functional state of CAC by the level of excretion of all CA fractions with a parallel study of the composition of LPO in women of fertile age with MS was not conducted.

Objective: To study the relationship between disorders of the functional state of the sympathetic-adrenal system (SAS) and lipid peroxidation processes in women of fertile age with metabolic syndrome.

Materials and methods. 91 women aged 25-49 years, who were randomly assigned to the following 3 groups, were examined in a hospital setting: I (control group – - healthy individuals aged

6	ISSN 2277-3630 (online), Published by International journal of Social Sciences & Interdisciplinary Research., under Volume: 13 Issue: 11 in November-2024 https://www.gejournal.net/index.php/IJSSIR
	Copyright (c) 2024 Author (s). This is an open-access article distributed under the terms of Creative Commons Attribution License (CC BY). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/

25-40 years – 15 people; II - patients with arterial hypertension – 39 people aged 29-49 years; III The group consisted of 37 women aged 26-49 years with arterial hypertension in combination with MS.

The following methods were used to diagnose MS:

1. The body mass index (BMI) was determined by the formula: weight (kg)/height (m)². According to the WHO classification, body weight is considered excessive if the BMI exceeds 24.9.

2. Abdominal obesity was determined by measuring the waist circumference (OT) between the edge of the lower rib and the iliac wing. As a physiological indicator, we took: for women less than 80 cm.

3. To determine metabolic disorders in patients, the level of total cholesterol (CH), triglycerides, very low-density lipoproteins (VLDL), LDL, high-density lipoproteins (HDL), and the coefficient of atherogenicity were studied (the lipid spectrum was determined biochemically by an express analyzer "Reflotron-Roche"), blood glucose (glucose oxidase method). The general clinical examination was carried out according to generally accepted programs (clinical analysis of blood, urine, ECG, X-ray examination of the chest, etc.). Determination of epinephrine (A), norepinephrine (NA), dopamine (DA), and DOPA in daily urine was performed by the trioxindole fluorimetric method modified by E. Sh.Matlina, Z. M. Kiseleva, and I. E. Sofieva (1965). Determination of the content of catecholamine (CA) conjugates in urine was performed according to the method described by T. I. Lukicheva, V. V. Menshikov, and T. D. Bolshakova (1971). The blood CA level was determined by ELISA on the device CatCombi ELISA. LPO products in blood serum were determined by the method of B. V. Gavrilov et al. (1987), MAO in the blood – according to the method of A. I. Balaklevsky (1976). The results of clinical trials were processed using the applied statistical processing programs of the Excel program, as well as by the method of variation statistics using Student t-criteria tables. Differences between the arithmetic mean values were considered statistically significant at p<0.05.

Results and discussion. As can be seen from Table 1, the maximum level of total cholesterol, triglycerides, LDL is noted in III group, compared to the control group and II in groups. In comparison with the control group, the total cholesterol level in patients with hypertension increased by 30.4%, and in women with MS - by 47.8%. Triglyceride content in III the group exceeded the control value by 71%, in II the group increased by 44.4%. Vo LDL level II in this group, it exceeded the indicator of the control group by 53.8%, the LDL content in the III increased by 99.7% compared to the healthy group. Vo's HDL II and in III It was reduced in both groups compared to the control group. When comparing the first and second groups, the difference in blood glucose level was 8.8%, and when comparing the first and second groups, the difference in blood glucose level was 8.8%. I and III groups – 46.6%.

Table 1.

Content of lipids and glucose in blood serum in practically healthy patients with arterial hypertension and metabolic syndrome

Groups	Total HC, mmol/l	Triglycerides, mmol / l	LDL, mmol / l	HDL, mmol / l	VLDL, mmol / l	The atherogen index., units	Glucose plasma volume, mmol/l
Group I	4,6±0,1	1,5±0,1	2,6±0,2	1,4±0,1	0,4±0,1	2,8±0,3	4,5±0,2
Group II	6,0±0,2	1,8±0,2	4,0±0,2	1,2±0,3	0,5±0,2	4,0±0,2	4,9±0,2
Group III	6,8±0,3	2,6±0,1	5,2±0,3	0,9±0,4	0,7±0,3	5,2±0,2	6,6±0,3

P 1-2	P<0.001	P<0.05	P<0.001	P<0.05	P<0.05	P<0.01	P<0.05
P 1-3	P<0.001	P<0.001	P<0.001	P<0.05	P<0.05	P<0.001	P<0.001
P 2-3	P<0.05	P<0.001	P<0.01	P<0.05	P<0.05	P<0.001	P<0.01

Table 2 shows the average values of daily urinary excretion of CA in all the examined groups. During the study, we noted a statistically significant increase in the excretion of A and HA in the daily urine of patients with hypertension and MS. So, daily excretion total And in patients with hypertension with healthy faces, it is increased by 43.9% (P<0.001), a total of 39.2%. Daily urinary excretion of all DA and DOPA fractions in patients with hypertension is statistically significantly lower than the control level. The elimination of free, conjugated, and total A and HA in MS patients was statistically significantly higher than in healthy subjects. The difference in DOPA excretion in MS was 27.8% (P<0.01). Table 2 shows the results of the study of A and NA in the blood of healthy women and patients with hypertension and MS. When analyzing the indicators, we noted a significant increase in the content of A and NA in patients compared to the control group. (For example, the level of A in MS patients was 3 times higher than in healthy patients, and in AH patients it was 1.5 times higher. The content of NA in the blood of MS patients was increased 2.7 times in the control group, and 1.4 times in comparison with the examined AH patients.) When analyzing the MDA data, we noted a statistically significant increase in the content in group III compared to group I by 102.7%, and the difference between groups I and II was 41.1%. The MAO study showed a statistically significant decrease in its level in groups II and III (P<0.001).

Table 2

The content of epinephrine and norepinephrine, MAO and MDA activity in the blood of practically healthy people and patients with metabolic syndrome

Groups	Epinephrine, nmol / l	Norepinephrine, nmol / l	MDA nmol / ml.	MAO, ed / ex.
I	0,76±0,2	2,68±0,2	3,4±0,3	0,08±0,002
II	1,9±0,1	5,9±0,1	4,8±0,2	0,054±0,0029
III	2,2±0,2	6,7±0,2	6,9±0,4	0,042±0,003
P-1-2	p<0.001	p<0.001	p<0.01	p<0.001
P-1-3	p<0.001	p<0.001	p<0.01	p<0.001
R-2-3	p<0.05	p<0.001	p<0.01	p<0.001

Thus, we found a statistically significant increase in the daily excretion of free and conjugated forms of CA (A, NA, DA) in MS patients. In the blood plasma of these patients, there was a significant and statistically significant increase in the content of cholesterol, lipoproteins, CA and LPO products, and MAO was also reduced. Thus, the results of the conducted studies showed that in MS, CA activation occurs, expressed by an increase in the content of A and HA in the blood and urinary excretion of CA (A, HA, DA, their DOPA precursor). A further increase in the intensity of CAC activity is aimed at mobilizing the internal reserves of the body. However, at one of the stages of this process, the catabolic orientation of the effects of SAS begins to manifest, and the further increase in the activity of which becomes one of the main elements in the formation of this pathology and its complications [2, 12].

According to our research results, there is a decrease in the catalytic activity of MAO, which is associated with the activation of POL and a qualitative change in the properties of MAO. Our results indicate an increased intensification of LPO processes in MS. Based on our clinical data, it

was possible to assume that disorders of CA metabolism in MS could have pathogenetic significance. At the same time, perhaps the main role should have been assigned to the strengthening of GENDER in this pathology. It could be expected that if LPO intensification plays an important role in biogenic amine metabolism disorders, then in the body of MS patients there could be analogies with a number of other pathological processes in which LPO products accumulate.

Conclusion. A study of patients with metabolic syndrome showed a change in the functional activity of the sympathetic-adrenal system and biogenic amine metabolism, which is expressed by an increase in the content of epinephrine and norepinephrine in the blood and increased urinary excretion of free and conjugated forms of catecholamines, and therefore an early correction is necessary to prevent the development of complications. Also, in the metabolic syndrome, there is a marked decrease in the activity of the key catecholamine deamination enzyme (MAO), as a result of which their long-term toxic effect on the myocardium occurs. In the metabolic syndrome, there is a significant activation of lipid peroxidation products, which is of great interest in identifying the mechanism of development of the metabolic syndrome.

Literature:

1. Giordano M., Matsuda M., Sanders L. et al. Effects of angiotensin-converting enzyme inhibitors. Ca channel antagonists and adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. *Diabetes* 1995.44. 665-671.
2. Mamedov M. N. Metabolic syndrome: practical aspects of diagnosis and treatment in outpatient settings. Manual for doctors. Moscow; 2005.6-33.
3. Chibisov S. M., Rapoport S. I., Kolesnikov D. B., Loboda A. Y. Metabolic syndrome: more questions than answers. *Clinical information the medicine*; №6. 2008. 30-35.
4. Esler M., Rumanier., Wiesner G. et al. Sympathetic nervous system and insulin resistance. From obese to diabetes. *Am. J. Hypertens.* 2001.14: 304-309.
5. Ogonov R. G., Perova N. V., Shchelstina N. V. et al. Manifestations of the metabolic syndrome in combination with arterial hypertension and individual coronary risk factors. *Kardiologiya* 2005.№7.27-33.
6. Sokolov E. I., Simonenko V. B., Zykova A. A., Srednyakov A.V. Clinical significance of insulin resistance detection in women with metabolic syndrome. *Kardiologiya* 2006; 4: 24-29.
7. Mamedov M. N. Arterial hypertension in the framework of the metabolic syndrome: features of the course and principles of drug correction. *Kardiologiya* 2004; No. 4. 95-100.
8. Bagdade J.D., Buchanan W.F., Pollare T., Lithell H. Abnormal lipoprotein phospholipid composition in patients with essential hypertension. *Atherosclerosis* 1995;117:209-215.
9. Vasiliev V. N., Chugunov V. S. Sympathetic-adrenal activity in various functional states of a person. *M. Meditsina*; 1985.272.
10. Khuzhamberdiev M. A. On disorders and ways of normalization of biogenic amine metabolism in atherosclerosis and coronary heart disease: Dissertation of the Doctor of medical sciences.- Moscow, 1985.